CN111436597B - Lipotide and its production process - Google Patents
Lipotide and its production process Download PDFInfo
- Publication number
- CN111436597B CN111436597B CN202010252471.7A CN202010252471A CN111436597B CN 111436597 B CN111436597 B CN 111436597B CN 202010252471 A CN202010252471 A CN 202010252471A CN 111436597 B CN111436597 B CN 111436597B
- Authority
- CN
- China
- Prior art keywords
- mixture
- parts
- weight
- vitamin
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 235000015097 nutrients Nutrition 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 39
- 239000003094 microcapsule Substances 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 21
- 238000005303 weighing Methods 0.000 claims description 19
- 108010046377 Whey Proteins Proteins 0.000 claims description 18
- 102000007544 Whey Proteins Human genes 0.000 claims description 18
- 235000021119 whey protein Nutrition 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- 229920001202 Inulin Polymers 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 12
- 229940029339 inulin Drugs 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 11
- 108010035532 Collagen Proteins 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 235000021388 linseed oil Nutrition 0.000 claims description 11
- 239000000944 linseed oil Substances 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 9
- 241000251511 Holothuroidea Species 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- 240000000599 Lentinula edodes Species 0.000 claims description 9
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 108010038807 Oligopeptides Proteins 0.000 claims description 9
- 102000015636 Oligopeptides Human genes 0.000 claims description 9
- 241000209140 Triticum Species 0.000 claims description 9
- 235000021307 Triticum Nutrition 0.000 claims description 9
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 9
- 235000021323 fish oil Nutrition 0.000 claims description 9
- 229960000306 zinc gluconate Drugs 0.000 claims description 9
- 235000011478 zinc gluconate Nutrition 0.000 claims description 9
- 239000011670 zinc gluconate Substances 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 7
- 239000004376 Sucralose Substances 0.000 claims description 7
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 claims description 7
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 claims description 7
- 235000013896 disodium guanylate Nutrition 0.000 claims description 7
- 235000013890 disodium inosinate Nutrition 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 235000019408 sucralose Nutrition 0.000 claims description 7
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- 238000012946 outsourcing Methods 0.000 claims description 2
- SLIUELDPAPMQIB-IDIVVRGQSA-N [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 Chemical compound [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 SLIUELDPAPMQIB-IDIVVRGQSA-N 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 235000019658 bitter taste Nutrition 0.000 claims 1
- 239000004194 disodium inosinate Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 230000035764 nutrition Effects 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 235000013325 dietary fiber Nutrition 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000011159 matrix material Substances 0.000 abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- -1 mannose oligosaccharide Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides the field of foods and special foods, and in particular relates to a lipopeptide and a production process thereof, wherein the lipopeptide comprises the following nutrients in parts by weight: 45-55 parts of protein, 20-25 parts of fat, 15-25 parts of carbohydrate, 5-10 parts of dietary fiber, 0.3-0.6 part of sodium, 0.01-0.02 part of vitamin E, 0.1-0.3 part of vitamin C and 0.008-0.012 part of zinc; aiming at the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of nutritional products of tumor patients, the invention provides the lipopeptide which is reasonably matched with protein, fat, dietary fiber and the like, and particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid is prepared, so that the characteristics of quick nutrition absorption, high value and the like are realized, and the supply of the protein and energy requirements of the patients is greatly improved.
Description
Technical Field
The invention relates to the field of foods and special foods, in particular to a lipopeptide and a production process thereof.
Background
Tumor itself is a wasting disease, and patients commonly have malnutrition, and weight loss is not only the main symptom of tumor patients, but also the cause of worsening prognosis. Patients with non-terminal-stage tumors often cannot perform surgery, radiation or chemotherapy due to worsening of the disease condition caused by malnutrition, but if the patients are well-configured with nutrition, the probability of worsening of the disease condition of the patients can be avoided or reduced to a certain extent by adopting nutrition therapy, so that the effect of improving the disease condition is achieved.
The highest goals of nutritional therapy are metabolic regulation, tumor control, quality of life improvement, and survival prolongation, and the basic requirements are to meet more than 70% of the target energy demand and 100% of the protein demand of tumor patients.
Disclosure of Invention
In order to overcome the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of nutrition for tumor patients in the prior art, the invention provides the lipopeptide which is reasonably matched with protein, fat, dietary fiber and the like, and particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid is prepared, so that the characteristics of quick nutrition absorption, high value and the like are realized, and the supply of the protein and energy requirements of patients is greatly improved.
The invention is realized by the following technical scheme.
The lipopeptide comprises the following nutrients in parts by weight:
preferably, the nutritional ingredients include, in parts by weight:
preferably, the protein source is one or more of isolated whey protein, short peptides, amino acids, casein, sodium caseinate. The purity of the separated whey protein is 88-95%, and the separated whey protein is processed by the technologies of filtering, drying and the like on the basis of concentrating the whey protein, so that lactose in the separated whey protein is completely removed, and the separated whey protein has the characteristic of quick absorption.
Preferably, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
Preferably, the amino acid is one or more of arginine, glutamine and leucine.
Preferably, the fat source is one or more of medium chain triglyceride microcapsule powder, linseed oil microcapsule powder and fish oil microcapsule.
Preferably, the dietary fiber source is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligomer, microcrystalline cellulose.
Preferably, the raw material sources comprise the following components in parts by weight:
preferably, the composition further comprises an immunonutrient, wherein the immunonutrient is contained in an amount of 1.2-7 parts by weight.
Preferably, the source of the immunonutrient is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soybean phospholipid, citric acid, zinc gluconate, and Lentinus edodes extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
preferably, the calcium beta-hydroxy-beta-methylbutyrate is also included, and the content of the calcium beta-hydroxy-beta-methylbutyrate is 1-3 parts by weight.
The invention also provides a production process of the lipopeptide, which comprises the following steps:
step one: weighing 0.02-0.07 weight part of sucralose, 0.01-0.05 weight part of disodium 5 '-guanylate, 0.01-0.05 weight part of disodium 5' -inosinate, 0.08-0.2 weight part of zinc gluconate, 0.02-0.06 weight part of vitamin E and 0.15-0.3 weight part of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of mannose oligomer, 0.2-0.7 part by weight of lentinus edodes extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter shielding essence and 0.2-0.7 part by weight of milk essence. Mixing the first mixture and the second mixture in a three-dimensional mixer, and sieving with a 40-mesh sieve to form a second mixture;
step three: weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of beta-hydroxy-beta-methylbutyrate calcium, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule. And putting the first mixed material and the second mixed material into a three-dimensional mixer for mixing to form a third mixed material;
step four: weighing 1-9 parts by weight of inulin, 5-9 parts by weight of collagen peptide, 8-20 parts by weight of linseed oil microcapsule powder and 2-6 parts by weight of arginine. Mixing the mixture and the third mixture in a three-dimensional mixer, and sieving the mixture with a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the mixture and the fourth mixture into a square cone mixer for mixing to obtain the required lipopeptid.
Preferably, the mixing frequency of the three-dimensional mixer in the second step, the third step and the fourth step is 40Hz, and the mixing time is 30min. And wherein the capacity of the three-dimensional mixer in the second step is 20L, and the capacity of the three-dimensional mixer in the third step and the fourth step is 200L.
Preferably, in the fifth step, the mixing speed of the square cone mixer is 9rpm, the mixing time is 45min, and the capacity is 600L.
Glutamine can enhance intestinal barrier, and can maintain gastrointestinal flora balance and promote nutrient absorption in combination with various dietary fibers (resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligosaccharide, and microcrystalline cellulose).
The active polysaccharide and the polymer thereof have good pharmacological activity in various aspects of immunoregulation, anti-tumor, anti-inflammatory, anti-radiation, cholesterol reduction, blood pressure reduction, thrombus resistance and the like.
The lentinan can induce the generation of immunocompetent cytokines to play a role in defending and killing tumor cells, and can be used in combination with other treatment means, so that the inhibition of surgery and radiotherapy and chemotherapy on immune functions can be relieved, the chemotherapy tolerance can be increased, the survival rate can be improved, and the quality of life can be improved.
For patients receiving large cervical and abdominal surgeries, enteral nutrition containing immunomodulatory components (arginine, omega-3 fatty acids and nucleotides) may be considered for perioperative use.
The invention has the beneficial effects that:
the lipid chain peptide formula system formed by matching high-quality protein matrix, fat supply matrix, immune regulation factor, active polysaccharide, antioxidant and the like is adopted, the supply of protein and energy is considered, and the purposes of maintaining balanced and sufficient absorption of nutrition in a patient body are achieved in aspects of stimulating mTOR (mammalian target of glucose) channel, cholesterol synthesis, mitochondrial biosynthesis, calcium ion release in SR, satellite cell proliferation, inhibiting ubiquitin-proteasome system, inhibiting autophagy-caspase system and the like.
Detailed Description
The present invention will be described in further detail with reference to examples. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The lipopeptide comprises the following nutrients in parts by weight:
as a preferred embodiment, the nutritional ingredients include, in parts by weight:
as a preferred embodiment, the protein source is one or more of isolated whey protein, short peptides and amino acids. The purity of the separated whey protein is 88-95%, and the separated whey protein is processed by technologies such as secondary filtration, drying and the like on the basis of concentrating the whey protein, so that lactose in the WPC is completely removed, and the separated whey protein has the characteristic of quick absorption.
As a preferred embodiment, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
As a preferred embodiment, the amino acid is one or more of arginine, glutamine and leucine.
As a preferred embodiment, the fat source is one or more of linseed oil microcapsule powder, fish oil microcapsule, and medium chain triglyceride microcapsule powder.
As a preferred embodiment, the dietary fiber source is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligocarbonate, microcrystalline cellulose.
As a preferred embodiment, the raw material sources comprise the following components in parts by weight:
as a preferred embodiment, the composition further comprises an immunonutrient, wherein the immunonutrient is contained in an amount of 1.2-7 parts by weight.
As a preferred embodiment, the source of the immunonutrient is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soybean lecithin, citric acid, zinc gluconate, and shiitake extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
as a preferred embodiment, it further comprises calcium beta-hydroxy-beta-methylbutyrate in an amount of 1 to 3 parts by weight.
The invention also provides a production process of the lipopeptide, which comprises the following steps:
step one: weighing 0.02-0.07 weight part of sucralose, 0.01-0.05 weight part of disodium 5 '-guanylate, 0.01-0.05 weight part of disodium 5' -inosinate, 0.08-0.2 weight part of zinc gluconate, 0.02-0.06 weight part of vitamin E and 0.15-0.3 weight part of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of mannose oligomer, 0.2-0.7 part by weight of lentinus edodes extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter shielding essence and 0.2-0.7 part by weight of milk essence. Mixing the first mixture and the second mixture in a three-dimensional mixer, and sieving with a 40-mesh sieve to form a second mixture;
step three: weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of beta-hydroxy-beta-methylbutyrate calcium, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule. And putting the first mixed material and the second mixed material into a three-dimensional mixer for mixing to form a third mixed material;
step four: weighing 1-9 parts by weight of inulin, 5-9 parts by weight of collagen peptide, 8-20 parts by weight of linseed oil microcapsule powder and 2-6 parts by weight of arginine. Mixing the mixture and the third mixture in a three-dimensional mixer, and sieving the mixture with a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the mixture and the fourth mixture into a square cone mixer for mixing to obtain the required lipopeptid.
As a preferred embodiment, the mixing frequency of the three-dimensional mixer in the second step, the third step and the fourth step is 40Hz, and the mixing time is 30min. And wherein the capacity of the three-dimensional mixer in the second step is 20L, and the capacity of the three-dimensional mixer in the third step and the fourth step is 200L.
As a preferred embodiment, the mixing speed of the square cone mixer in the fifth step is 9rpm, the mixing time is 45min, and the capacity is 600L.
The beneficial effects of this patent are further described by the specific five sets of examples.
Table 1 material formulation of lipopeptides
The formula of each raw material in the embodiment is shown in table 1, and the production process of the lipopeptid formed by five groups of formulas is specifically as follows:
(1) Preparation of materials
The method comprises the steps of obtaining separated whey protein, linseed oil microcapsule powder, medium-chain triglyceride microcapsule powder, collagen peptide, arginine, inulin, fish oil microcapsule, glutamine, beta-hydroxy-beta-methylbutyrate calcium, leucine, wheat oligopeptide, sea cucumber peptide, lentinus edodes extract, mannose oligomer, isomaltulose, vitamin C, vitamin E, zinc gluconate, disodium 5 '-guanylate, disodium 5' -inosinate, soybean phospholipid, microcrystalline cellulose, citric acid, bitter screening essence, milk essence and sucralose.
(2) Mixing
And weighing and uniformly mixing sucralose, disodium 5 '-guanylate, disodium 5' -inosinate, zinc gluconate, vitamin E and vitamin C according to the formula amount to form a first mixture.
Weighing mannose oligomer, lentinus Edodes extract, sea cucumber peptide, bitter shielding essence and milk essence, mixing with the first mixture in a three-dimensional mixer at 40Hz for 30min, and sieving with 40 mesh sieve to obtain second mixture.
Weighing citric acid, microcrystalline cellulose, soybean lecithin, isomaltulose, wheat oligopeptide, leucine, beta-hydroxy-beta-methylbutyrate calcium, glutamine and fish oil microcapsules according to the formula amount, and placing the microcapsules and the second mixture into a three-dimensional mixer to be mixed for 30min at the frequency of 40Hz to form a third mixture.
Weighing inulin, collagen peptide, linseed oil microcapsule powder and arginine according to the formula amount, putting the inulin, collagen peptide, linseed oil microcapsule powder and arginine and the third mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving with a 40-mesh screen to form a fourth mixture.
The medium chain triglyceride microcapsule powder and the separated whey protein with the formula amount are weighed, and are put into a square cone mixer together with the fourth mixture to be mixed for 45min at the rotating speed of 9 rpm.
By adopting a gradient mixing dry process, various materials can be fully and uniformly mixed.
(3) Inner bag
And transferring the mixed materials to an inner package room for packaging.
(4) Outsourcing
And transferring the product finished by the inner package to an outer package room for packaging.
Test example 1
Effect on body weight of H22 tumor-bearing mice
Test group:
test 1 group: cisplatin for injection (20 mg/min, manufactured by zilutu pharmaceutical Co., ltd.).
Test 2 group: cisplatin for injection (20 mg/min, manufactured by zilutu pharmaceutical Co., ltd.) +example II.
The test method comprises the following steps: collecting Kunming mice (male, body weight 18-22 g); extracting ascites of H22 liver cancer mice passaged for 7d in abdominal cavity under aseptic condition, and regulating cell concentration to 1×10 with physiological saline 7 /ml. The H22 tumor cell suspensions were inoculated, 0.2ml each, subcutaneously in the right axilla of kunming mice, according to the anticancer drug study screening protocol. After 7d inoculation of H22 liver cancer cells, selecting tumor body as 100mm 3 The left and right mice were grouped into control group, test 1 group, test 2 group, test 1 group dailyCisplatin is injected into the abdominal cavity at a concentration of 10mg/kg, 1 time a day; the test group 2 was intraperitoneally injected with cisplatin 10mg/kg daily, and the second group of examples was given 4.5g/kg by gavage 1 time daily; the control group is infused with 0.4ml of physiological saline for stomach every day, 1 time every day; after 12d of continuous administration, the mice were weighed and the test results are shown in Table 2.
TABLE 2 influence of Lipopeptides of the invention in combination with cisplatin on H22 tumor-bearing mice weight
Note that: p <0.01 compared to control group; compare #p <0.05 to trial 1.
Conclusion of the test: the experiment shows that after cisplatin treatment, the weight of the mice is increased, but the weight of the mice is obviously increased by adding the lipopeptides, which further shows that the lipopeptides have good effect on supplementing nutrition to cancer patients.
Test example 2
Clinical pre-experiment: the lipopeptides obtained in example two are useful for clinical nutrition of malignant tumors.
50 patients with malignant tumor were randomly selected, with ages ranging from 30-60 years, average age of 48.6 years, with 23 females and 27 males. When the medicine is eaten, about 150ml of warm water is measured, the medium is added into the first bag of the lipopeptide in the second embodiment, and the medicine is drunk after being fully and uniformly stirred for 3 months, and the treatment of other medicines is not stopped within 3 months according to the doctor's advice. The related indexes of albumin, C-reactive protein, albumin and interleukin-6 before and after 3 months of patients are tested, wherein the related indexes before and after treatment are shown as follows:
TABLE 3 changes in the indices of malignancy patients before and after treatment
Prealbumin (mg/L) | C reactive protein (mg/L) | Albumin (g/L) | Interleukin-6 (pg/ml) | |
Before treatment | 146±47.31 | 36±14.86 | 33±3.24 | 28±6.81 |
After treatment | 162±64.86 | 26±20.32 | 45±4.61 | 22±4.58 |
P | 0.054 | 0.028 | 0.008 | 0.013 |
It can be seen from the table that after the lipopeptid is eaten, the nutrition state of a malignant tumor patient is improved relatively, the blood albumin and the albumin can be steadily improved, the physical ability of the patient is improved, the immunity is increased, the effect of resisting inflammatory factors is enhanced, various cytokines are balanced in the body, the disease progress is effectively relieved, and the risk of disease deterioration is reduced.
While the foregoing description illustrates and describes the preferred embodiments of the present invention, as noted above, it is to be understood that the invention is not limited to the forms disclosed herein but is not to be construed as excluding other embodiments, and that various other combinations, modifications and environments are possible and may be made within the scope of the inventive concepts described herein, either by way of the foregoing teachings or by those of skill or knowledge of the relevant art. And that modifications and variations which do not depart from the spirit and scope of the invention are intended to be within the scope of the appended claims.
Claims (1)
1. The lipopeptides are characterized by comprising the following nutrients in parts by weight:
isolated whey protein 40, linseed oil microcapsule powder 10, medium chain triglyceride microcapsule powder 20, collagen peptide 9, arginine 2, inulin 2, fish oil microcapsule 1, glutamine 0.8, beta-hydroxy-beta-methylbutyrate calcium 1, leucine 0.8, wheat oligopeptide 0.8, soybean lecithin 3, citric acid 2.4, microcrystalline cellulose 0.5, isomaltulose 0.5, lentinus edodes extract 0.2, sea cucumber peptide 0.3, mannose oligomer 0.7, vitamin C0.3, vitamin E0.06, zinc gluconate 0.2,5 '-disodium inosinate 0.01,5' -guanylate 0.05, bitter taste masking essence 0.4, milk essence 0.7 and sucralose 0.07;
the preparation method of the lipopeptid comprises the following steps:
(1) Preparation of materials
Collecting separated whey protein, linseed oil microcapsule powder, medium-chain triglyceride microcapsule powder, collagen peptide, arginine, inulin, fish oil microcapsule, glutamine, beta-hydroxy-beta-methylbutyrate calcium, leucine, wheat oligopeptide, sea cucumber peptide, lentinus edodes extract, oligomeric mannose, isomaltulose, vitamin C, vitamin E, zinc gluconate, 5 '-guanylate disodium, 5' -inosinic acid disodium, soybean phospholipid, microcrystalline cellulose, citric acid, bitter screening essence, milk essence and sucralose;
(2) Mixing
Weighing sucralose, disodium 5 '-guanylate, disodium 5' -inosinate, zinc gluconate, vitamin E and vitamin C according to the formula amount, and uniformly mixing to form a first mixture;
weighing mannose oligomer, lentinus Edodes extract, sea cucumber peptide, bitter shielding essence and milk essence, mixing with the first mixture in a three-dimensional mixer at 40Hz for 30min, and sieving with 40 mesh sieve to obtain second mixture;
weighing citric acid, microcrystalline cellulose, soybean lecithin, isomaltulose, wheat oligopeptide, leucine, beta-hydroxy-beta-methylbutyrate calcium, glutamine and fish oil microcapsules with the formula amount, and putting the microcapsules and the second mixture into a three-dimensional mixer to be mixed for 30min at the frequency of 40Hz to form a third mixture;
weighing inulin, collagen peptide, linseed oil microcapsule powder and arginine according to the formula amount, putting the inulin, collagen peptide, linseed oil microcapsule powder and arginine and the third mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving with a 40-mesh screen to form a fourth mixture;
weighing medium chain triglyceride microcapsule powder with a formula amount, separating whey protein, and putting the medium chain triglyceride microcapsule powder and the fourth mixture into a square cone mixer to be mixed for 45min at a rotating speed of 9 rpm;
the gradient mixing dry process is adopted, so that various materials can be fully and uniformly mixed;
(3) Inner bag
Transferring the mixed materials to an inner packing room for packing;
(4) Outsourcing
And transferring the product finished by the inner package to an outer package room for packaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010252471.7A CN111436597B (en) | 2020-04-01 | 2020-04-01 | Lipotide and its production process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010252471.7A CN111436597B (en) | 2020-04-01 | 2020-04-01 | Lipotide and its production process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111436597A CN111436597A (en) | 2020-07-24 |
CN111436597B true CN111436597B (en) | 2023-05-12 |
Family
ID=71649564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010252471.7A Active CN111436597B (en) | 2020-04-01 | 2020-04-01 | Lipotide and its production process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111436597B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113841889A (en) * | 2021-08-10 | 2021-12-28 | 许昌学院 | Cell absorption combined functional nutrient |
CN116036247B (en) * | 2023-02-03 | 2024-04-05 | 江中药业股份有限公司 | Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109846029A (en) * | 2018-11-23 | 2019-06-07 | 广州欧普康特医食品有限公司 | A kind of Elental for cancer patient |
CN110839884A (en) * | 2019-12-04 | 2020-02-28 | 上海张新生物医药科技有限公司 | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof |
CN110892985A (en) * | 2019-11-28 | 2020-03-20 | 北京诺康达医药科技股份有限公司 | Nutritional preparation suitable for perioperative patients |
-
2020
- 2020-04-01 CN CN202010252471.7A patent/CN111436597B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109846029A (en) * | 2018-11-23 | 2019-06-07 | 广州欧普康特医食品有限公司 | A kind of Elental for cancer patient |
CN110892985A (en) * | 2019-11-28 | 2020-03-20 | 北京诺康达医药科技股份有限公司 | Nutritional preparation suitable for perioperative patients |
CN110839884A (en) * | 2019-12-04 | 2020-02-28 | 上海张新生物医药科技有限公司 | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111436597A (en) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106616615A (en) | Clinical nutrient formula special for tumor and preparation method of clinical nutrient formula | |
CN107549612B (en) | Nutritional formula rice flour capable of improving immunity of 6-12 month-old infants | |
CN111436597B (en) | Lipotide and its production process | |
CN104432012A (en) | Dendrobium compound superfine powder and preparation method thereof | |
CN112089051A (en) | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof | |
CN113575934A (en) | Total-nutrient compound protein powder for tumor patients | |
CN109619552A (en) | Suitable for the nutrition treatment type formula and preparation method of tumor patient, purposes | |
CN107981339A (en) | Tumour full nutrition formula food | |
CN105410932A (en) | Tumor immunity type nutritional composition and application thereof | |
CN104738638A (en) | Composition with anti-fatigue effect and application thereof | |
CN106376934A (en) | Ketogenic-diet composition containing active polysaccharide, and preparation and application methods thereof | |
CN111449247A (en) | Tumor patient sea cucumber peptide nutritional supplement and processing method thereof | |
CN111480839A (en) | Special clinical nutrition formula for bone cancer and preparation method thereof | |
CN110150654A (en) | A kind of special medicine purposes formula food for tumor patient | |
CN111802633A (en) | Special clinical nutrition formula for esophageal cancer and preparation method thereof | |
CN108783465A (en) | A kind of nutrition formula product with oncotherapy function | |
CN114868890A (en) | Multi-vitamin nutrient formula suitable for tumor patients | |
CN102228181B (en) | Composition eaten by cancer patients and containing oligopeptide and chitosan oligosaccharide | |
CN113244246B (en) | Application of microbial plasmalogen in treatment of colon cancer | |
CN101167760B (en) | Mushroom fermentation oral liquid with anti-tumor activity and preparation method | |
CN101574145A (en) | Nutritional reinforced supplement | |
CN115053929A (en) | Formula milk powder suitable for people with fatty liver and preparation method thereof | |
CN114796458A (en) | Steam equipment multivitamin for adjuvant therapy of tumors and preparation method and application thereof | |
CN112544712A (en) | Lentinan soluble bean for improving intestinal immunity of children by diet and preparation method thereof | |
CN110419721A (en) | A kind of tumour tailored version clinic special dietary formula and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |